Exicure (XCUR) said late Thursday it signed a memorandum of understanding with GPCR Therapeutics for the acquisition of the South Korean company's US subsidiary, GPCR USA, to advance its growth as a clinical-stage biotech firm.
Exicure plans to purchase all the shares of GPCR USA to secure key technical personnel. The financial terms of the acquisition weren't disclosed.
The MoU also includes the technology transfer of GPCR Therapeutics' CXCR4 inhibitor, which is currently in phase 2 clinical trials with the Food and Drug Administration.
Exicure also aims to carry out collaborative research and development with GPCR Therapeutics for its ongoing research in immuno-oncology, fibrosis treatments and obesity therapies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。